What front line therapy would you recommend for a patient with CLL on chronic dual antiplatelet therapy?  

How would your choice of therapy differ (if at all) for high vs low risk disease?

Would the specific anti-platelet agents used influence your choice above?

Are there any circumstances where you would give a BTK inhibitor with concurrent dual anti-platelet therapy?

Answer from: Medical Oncologist at Academic Institution